UTRECHT, the Netherlands–(BUSINESS WIRE)–Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of Miriam Bujny, Ph.D., as Chief Development Officer. With over ten years of experience in drug discovery, translational science and early stage clinical development, Dr. Bujny will apply her expertise in RNA and antibody therapeutic development to further advance Sapreme’s proprietary endosomal escape platform through preclinical development. Dr. Bujny will be based at Sapreme’s headquarters in Utrecht, The Netherlands, and will report to the CEO.
“Throughout my career, I have seen the limitations of developing promising therapeutic candidates due to the lack of delivery into key cells,” commented Dr. Bujny, Chief Development Officer of Sapreme. “Sapreme is developing a promising platform, that has the ability to improve the delivery and thereby the efficacy for a broad range of macromolecules such as antibody-conjugated toxins and antisense oligonucleotides. I look forward to applying my experience and knowledge toward Sapreme’s mission of developing next-generation macromolecule therapeutics.”
Commenting on the appointment, Guy Hermans, Chief Executive Officer of Sapreme said, “After recently announcing positive preclinical data on our proprietary endosomal escape platform, we are now concentrated on building out our team to accelerate the development of our compounds and identifying the full potential of our platform in the different therapeutic areas. Miriam’s experience in drug discovery and development as well as her demonstrated ability to strategically and operationally lead projects toward the next stage of development will be a valuable asset to us. We welcome Miriam to the team and look forward to working with her.”
Over the last ten years, Dr. Bujny has held leadership positions in various drug discovery and clinical development roles. Prior to joining Sapreme, Miriam worked at ProQR Therapeutics, a Dutch biotech company developing RNA therapies for severe genetic disorders, as Senior Director R&D. During her time at ProQR, she led the early development activities for a novel RNA therapy for Fuchs’ endothelial corneal dystrophy, a common inherited eye disease, from lead candidate optimization toward clinical development preparations. She also headed the Translational Science department and oversaw biomarker and assay development activities across a variety of RNA therapy programs for rare diseases. From 2012 to 2016, she worked in various roles for Janssen, part of the Pharmaceutical Companies of Johnson & Johnson, where she established and headed the predictive biomarker department at the Janssen Prevention Center. Before that, she worked on anti-viral antibody therapy development and contributed to early clinical development as preclinical in vitro lead. Prior to this, Miriam worked at Crucell, before its acquisition by Johnson & Johnson, in the Innovation & Discovery Labs on antibody discovery and engineering.
Dr. Bujny holds a Ph.D. in biochemistry from the University of Bristol with a specialization in endosomal transport. She completed postdoctoral training in the lab of Dr. Xiaowei Zhuang at Harvard University, specializing in developing imaging methods in order to apply them to biomedical questions.
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.